Atomi Financial Group Inc. Buys 142 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Atomi Financial Group Inc. lifted its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 19.6% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 867 shares of the medical equipment provider’s stock after acquiring an additional 142 shares during the period. Atomi Financial Group Inc.’s holdings in Intuitive Surgical were worth $346,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in ISRG. Pure Financial Advisors LLC grew its holdings in shares of Intuitive Surgical by 2.4% during the 4th quarter. Pure Financial Advisors LLC now owns 1,432 shares of the medical equipment provider’s stock worth $483,000 after purchasing an additional 34 shares in the last quarter. Wedmont Private Capital boosted its stake in Intuitive Surgical by 70.5% during the fourth quarter. Wedmont Private Capital now owns 4,029 shares of the medical equipment provider’s stock worth $1,325,000 after buying an additional 1,666 shares in the last quarter. Elevated Capital Advisors LLC increased its holdings in Intuitive Surgical by 8.9% in the 4th quarter. Elevated Capital Advisors LLC now owns 1,514 shares of the medical equipment provider’s stock valued at $511,000 after buying an additional 124 shares during the period. Capital Asset Advisory Services LLC raised its stake in shares of Intuitive Surgical by 2.7% in the 4th quarter. Capital Asset Advisory Services LLC now owns 5,695 shares of the medical equipment provider’s stock valued at $1,921,000 after buying an additional 148 shares in the last quarter. Finally, Dfpg Investments LLC lifted its holdings in shares of Intuitive Surgical by 7.2% during the 4th quarter. Dfpg Investments LLC now owns 6,694 shares of the medical equipment provider’s stock worth $2,156,000 after acquiring an additional 448 shares during the period. 83.64% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on ISRG shares. Stifel Nicolaus increased their price target on shares of Intuitive Surgical from $420.00 to $430.00 and gave the stock a “buy” rating in a research report on Monday, April 8th. Robert W. Baird dropped their target price on Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating for the company in a report on Friday, April 19th. BTIG Research upped their price target on Intuitive Surgical from $451.00 to $459.00 and gave the company a “buy” rating in a research report on Monday. Piper Sandler lifted their price objective on Intuitive Surgical from $435.00 to $490.00 and gave the company an “overweight” rating in a report on Tuesday, July 9th. Finally, Jefferies Financial Group upped their target price on shares of Intuitive Surgical from $365.00 to $375.00 and gave the stock a “hold” rating in a report on Friday, April 19th. Six analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat, Intuitive Surgical has an average rating of “Moderate Buy” and an average target price of $419.16.

Intuitive Surgical Trading Down 1.2 %

Shares of ISRG traded down $5.34 during trading hours on Monday, hitting $438.82. 1,101,807 shares of the stock traded hands, compared to its average volume of 1,502,784. The business has a fifty day moving average of $417.08 and a 200-day moving average of $391.15. The firm has a market capitalization of $155.65 billion, a PE ratio of 78.76, a price-to-earnings-growth ratio of 5.74 and a beta of 1.39. Intuitive Surgical, Inc. has a 1-year low of $254.85 and a 1-year high of $449.00.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.10. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The company had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.87 billion. During the same quarter last year, the firm earned $1.00 EPS. The company’s revenue for the quarter was up 11.5% on a year-over-year basis. As a group, equities research analysts expect that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current fiscal year.

Insider Buying and Selling at Intuitive Surgical

In related news, Director Alan J. Levy sold 2,000 shares of Intuitive Surgical stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $370.70, for a total transaction of $741,400.00. Following the completion of the sale, the director now directly owns 25,319 shares of the company’s stock, valued at $9,385,753.30. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, Director Alan J. Levy sold 2,000 shares of the stock in a transaction that occurred on Tuesday, April 23rd. The shares were sold at an average price of $370.70, for a total value of $741,400.00. Following the sale, the director now directly owns 25,319 shares in the company, valued at approximately $9,385,753.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Myriam Curet sold 5,318 shares of the stock in a transaction that occurred on Tuesday, April 23rd. The shares were sold at an average price of $370.66, for a total transaction of $1,971,169.88. Following the completion of the sale, the executive vice president now owns 298 shares in the company, valued at $110,456.68. The disclosure for this sale can be found here. In the last 90 days, insiders sold 17,956 shares of company stock worth $6,927,011. Insiders own 0.90% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.